Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$49.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Glaxosmithkline Plc and Genmab A/S Receive CHMP Positive Opinion for Arzerra in combination with Chlorambucil or Bendamustine


Friday, 23 May 2014 09:22am EDT 

Glaxosmithkline Plc and Genmab A/S:Committee for Medicinal Products for Human Use (CHMP) of European Medicines Agency (EMA) has issued positive opinion recommending variation to terms of marketing authorization.Says for Arzerra for new indication in combination with chlorambucil or bendamustine for treatment of patients with chronic lymphocytic leukemia (CLL) who have not received prior therapy and who are not eligible for fludarabine-based therapy. 

Company Quote

41.95
-0.31 -0.73%
6 Jul 2015